Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Total Liabilities: NT$23.77 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
43 GF Score
Price NT$75.20
GF Value NT$25.78
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Total Liabilities?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 -3.59% 43 Total Liabilities is NT$23.77 Mil as of Dec. 2025. GuruFocus rates ROCO:7427 with a GF Score™ of 43/100 and a GF Value™ of NT$25.78 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Great Novel Therapeutics Biotech & Medicals's Total Liabilities for the quarter that ended in Dec. 2025 was NT$23.77 Mil.

Great Novel Therapeutics Biotech & Medicals's quarterly Total Liabilities declined from Dec. 2024 (NT$29.28 Mil) to Jun. 2025 (NT$23.32 Mil) but then increased from Jun. 2025 (NT$23.32 Mil) to Dec. 2025 (NT$23.77 Mil).

Great Novel Therapeutics Biotech & Medicals's annual Total Liabilities increased from Dec. 2023 (NT$26.81 Mil) to Dec. 2024 (NT$29.28 Mil) but then declined from Dec. 2024 (NT$29.28 Mil) to Dec. 2025 (NT$23.77 Mil).

Great Novel Therapeutics Biotech & Medicals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Total Liabilities Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 21.61 12.05 26.81 29.28 23.77

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.81 29.88 29.28 23.32 23.77
ROCO:7427
43GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Great Novel Therapeutics Biotech & Medicals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.337+(4.433+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.77

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=526.752-502.982
=23.77

Great Novel Therapeutics Biotech & Medicals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.337+(4.433+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=23.77

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=526.752-502.982
=23.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of NT$23.77 Mil mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Total Liabilities of NT$23.77 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors.
Is Great Novel Therapeutics Biotech & Medicals' Total Liabilities too high?
Great Novel Therapeutics Biotech & Medicals' current Total Liabilities is NT$23.77 Mil. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Total Liabilities compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' Total Liabilities of NT$23.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Total Liabilities is NT$23.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.78, compared to a current price of NT$75.20 — trading 191.7% above its estimated fair value. The current Total Liabilities is NT$23.77 Mil. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Total Liabilities is NT$23.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$75.20 is trading 191.7% above its estimated GF Value™ of NT$25.78. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • Total Liabilities: NT$23.77 Mil
  • GF Value™: NT$25.78 vs. price of NT$75.20 (191.7% above fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
43GF Score

Get the complete analysis for ROCO:7427

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$75.20
Price
NT$25.78
GF Value